Álvaro Castellanos | Medicine | Innovation in Education Excellence Award

Published on by Global Academic Awards

Assoc. Prof. Dr. Álvaro Castellanos | Medicine | Innovation in Education Excellence Award

Assoc. Prof. Dr. Álvaro Castellanos, HOSPITAL UNIVERSITARIO Y POLITÉCNICO LA FE DE VALENCIA, Spain

Dr. Álvaro Castellanos Ortega is a highly esteemed Associate Professor of Medicine and the Head of the Intensive Care Department at Hospital Universitario y Politécnico La Fe in Valencia. He earned his Medical degree from the University of Valladolid and completed his PhD at the University of Cantabria. With extensive expertise in intensive care and medical education, Dr. Castellanos has contributed significantly to research in infection, sepsis, and training. He has authored 63 indexed publications, and his work on competence-based medical education has earned multiple prestigious awards, including the ESICM Trials Group Award. He is also actively involved in European medical education initiatives.

Publication Profile

Orcid

Professional Qualifications 🏥

Assoc. Prof. Dr. Álvaro Castellanos is a distinguished medical professional with a strong academic and clinical background. He graduated in Medicine and Surgery from the University of Valladolid (1979) and earned his PhD with honors from the University of Cantabria (1998), focusing on a prognostic scoring system for meningococcal septic shock in children. He specialized in Intensive Care Medicine, completing his training at Hospital Universitario Marqués de Valdecilla. Dr. Castellanos serves as Head of the Intensive Care Medicine Department at Hospital Universitario y Politécnico La Fe de Valencia. He is also an Associate Professor at the University of Valencia and an EDIC examiner. Additionally, he holds a Master’s in Healthcare Administration from the University of Cantabria. 🌟

 

 

Awards and Recognitions

Assoc. Prof. Dr. Álvaro Castellanos has earned numerous prestigious awards throughout his career. He won the First Prize for Quality Improvement of Care from the Regional Healthcare Service of Cantabria in 2008. His initiative on implementing the Surviving Sepsis Campaign during residency also received recognition. In 2017, he earned the First Prize for Best Patient Safety Initiatives for his rapid response system project. Dr. Castellanos was awarded the Best Project in Postgraduate Teaching by the Lilly Foundation for his electronic portfolio for specialists. Additionally, he received the ESICM Trials Group Award for his research on medical education in intensive care. 🌟

 

 

Research Focus

Dr. Álvaro Castellanos-Ortega is an Associate Professor with significant contributions in intensive care medicine, particularly related to medical education and patient safety in critically ill patients. He has been involved in multiple research projects focusing on pharmacokinetics in critically ill patients, including studies on Cefiderocol, Isavuconazole, and other medications. Dr. Castellanos-Ortega has authored and co-authored numerous articles on intensive care topics such as COVID-19 management, heart transplantation, and training programs for intensive care medicine. His work is widely published in journals like Medicina Intensiva and Critical Care, contributing significantly to the improvement of clinical practices in intensive care units.

 

 

Publication Top Notes

  • Effect of a Competence-Based Medical Education Program on Training Quality in Intensive Care Medicine. COBALIDATION TRIAL.
    Medicina Intensiva (2025-01-03)
    DOI: 10.1016/j.medine.2024.502126
    PMID: 39755447
    Contributors: Castellanos-Ortega Á, Broch Porcar MJ, Palacios-Castañeda D, et al.
  • Cefiderocol Pharmacokinetics in Critically Ill Patients Undergoing ECMO Support.
    Critical Care (2024-10-18)
    DOI: 10.1186/s13054-024-05126-4
    PMID: 39425201
    PMC: PMC11488226
    Contributors: Marín-Cerezuela M, Martín-Latorre R, Frasquet J, et al.
  • Reply to “Patient Safety, What Does Clinical Simulation and Teaching Innovation Contribute?”
    Medicina Intensiva (2024-10-05)
    DOI: 10.1016/j.medine.2024.07.013
    PMID: 39368886
    Contributors: Broch Porcar MJ, Castellanos-Ortega Á
  • Comparative Temporal Analysis of Morbidity and Early Mortality in Heart Transplantation with Extracorporeal Membrane Oxygenation Support: Exploring Trends Over Time.
    Biomedicines (2024-09-16)
    DOI: 10.3390/biomedicines12092109
    PMID: 39335622
    PMC: PMC11428817
    Contributors: López Vilella R, Pérez Guillén M, Borja Guerrero Cervera, et al.
  • Isavuconazole Pharmacokinetics in Critically Ill Patients: Relationship with Clinical Effectiveness and Patient Safety.
    Antibiotics (2024-07-29)
    DOI: 10.3390/antibiotics13080706
    PMID: 39200006
    PMC: PMC11350865
    Contributors: Martín Cerezuela M, Gallegos C, Marqués-Miñana MR, et al.
  • Patient Safety, What Does Clinical Simulation and Teaching Innovation Contribute?
    Medicina Intensiva (2024-05-25)
    DOI: 10.1016/j.medine.2024.04.012
    PMID: 38797620
    Contributors: Broch Porcar MJ, Castellanos-Ortega Á
  • “INTUPROS”: An Opportunity to Reflect Upon and Improve.
    Medicina Intensiva (2024-05-06)
    DOI: 10.1016/j.medine.2024.04.014
    PMID: 38714391
    Contributors: Viviani A, Vicent C, Castellanos-Ortega Á
  • Mentoring Programme: Guiding Your First Steps Towards Scientific Excellence.
    Medicina Intensiva (2023-03-21)
    DOI: 10.1016/j.medine.2023.03.006
    PMID: 36948924
    Contributors: Lobo-Valbuena B, Galarza Barrachina L, Albillos Almaraz R, et al.
  • Effects of Intubation Timing in Patients with COVID-19 Throughout the Four Waves of the Pandemic: A Matched Analysis.
    The European Respiratory Journal (2023-03-02)
    DOI: 10.1183/13993003.01426-2022
    PMID: 36396142
    PMC: PMC9686319
    Contributors: Riera del Brio J, Barbeta E, Tormos A, et al.
  • Driving Pressure and Adjunctive Therapies in Pulmonary Sequelae of COVID-19 Patients Under Invasive Ventilation.
    Intensive Care Medicine (2023-01-25)
    DOI: 10.1007/s00134-022-06951-3
    PMID: 36695836
    PMC: PMC9875751
    Contributors: González J, Iván David Benítez, Ana Motos, et al.

 

Min-ran Li | Medicine and Dentistry | Women Researcher Award

Published on by Global Academic Awards

Ms. Min-ran Li | Medicine and Dentistry | Women Researcher Award

Ms. Min-ran Li, The First Affiliated Hospital of Jinan University, China

Dr. Minran Li is the Chief Physician at the Division of Infectious Disease at The First Affiliated Hospital of Jinan University. He earned his M.D. in Internal Medicine from Peking University and has extensive expertise in infectious diseases, particularly nonalcoholic steatohepatitis (NASH) and chronic hepatitis B. His research focuses on discovering noninvasive biomarkers and the molecular mechanisms behind liver diseases. Dr. Li has published numerous articles and has been recognized as a Guangdong High-Level Personnel of Young Talents. 🏥📚

Publication Profile

Scopus

 

Education

Ms. Li holds an M.D. in Internal Medicine (Infectious Disease) from Beijing Peking University, a Master’s in Internal Medicine from Hebei Medical University, and a Bachelor’s in Clinical Medicine. This strong educational foundation has empowered her expertise in infectious diseases, particularly liver-related conditions like NASH (nonalcoholic steatohepatitis) and CHB (chronic hepatitis B).

Work Experience

Currently serving as Chief Physician in the Division of Infectious Diseases at the First Affiliated Hospital of Jinan University, Ms. Li has progressively taken on roles of increasing responsibility, including as Associate Chief Physician at The Fifth Hospital of Shijiazhuang. Her work centers on managing liver diseases and exploring innovative biomarkers.

Research Interests

Her research focuses on discovering noninvasive biomarkers for pathological features of NASH in combination with CHB. Her findings on the role of HIGD1A and fibrosis development in liver disease have been pivotal in identifying therapeutic targets, advancing the understanding of liver disease progression.

Awards and Recognitions

Her dedication has been recognized with honors such as the Guangdong High-Level Personnel of Young Talents Program and the Yangcheng Good Doctor Award, underscoring her excellence in medical research and practice.

Conclusion

Ms. Min-ran Li’s strong academic background, leadership in liver disease research, and national and international recognition make her a strong candidate for the Research for Women Researcher Award.

 

Publication Top Notes

  • Pan, Y. et al. (2024). Overexpression of LAG-3: a potential indicator of low immune function in tuberculosis. Frontiers in Cellular and Infection Microbiology, 14, 1410015. 🦠 (0 citations)
  • Li, M.-R. et al. (2024). The function role of HIGD1A in nonalcoholic steatohepatitis from chronic hepatitis B. Scandinavian Journal of Gastroenterology, 59(4), 445–455. 🥗 (0 citations)
  • Li, J.-Z. et al. (2023). Mechanism and Progress of Natural Products in the Treatment of NAFLD-Related Fibrosis. Molecules, 28(23), 7936. 🌿 (0 citations)
  • Li, M.-R. et al. (2023). Clinical Features of Non-Alcoholic Fatty Liver Disease in the Non-Lean Population. Obesity Facts, 16(5), 427–434. 🍔 (1 citation)
  • Pan, Y. et al. (2023). Immune checkpoint inhibitors in cancer patients with COVID-19. Open Life Sciences, 18(1), 20220641. 💉 (1 citation)
  • Li, J.-Z. et al. (2022). Characteristics and treatment strategies for hepatocellular carcinoma caused by nonalcoholic fatty liver disease. Zhonghua gan zang bing za zhi, 30(12), 1392–1396. 🏥 (0 citations)
  • Yang, L. et al. (2022). Progress in research of lipogenesis inhibitors for treatment of nonalcoholic fatty liver disease. World Chinese Journal of Digestology, 30(16), 735–742. 🧬 (1 citation)
  • Li, J.-Z. et al. (2021). The identify role and molecular mechanism of the MALAT1/hsa-mir-20b-5p/TXNIP axis in liver inflammation caused by CHB in patients with chronic HBV infection complicated with NAFLD. Virus Research, 298, 198405. 🔬 (20 citations)
  • Zheng, X.-L. et al. (2021). Effect of optimizing oxygen therapy on multiple organ function and prognosis of patients with COVID-19. Chinese Journal of Pathophysiology, 37(5), 909–914. 🫁 (0 citations)
  • Li, M.-R. et al. (2020). Clinical features of hepatitis B patients at immune-tolerance phase with basal core promoter and/or precore mutations. Journal of Viral Hepatitis, 27(10), 1044–1051. 🦠 (4 citations)